Troy Wil­son re­cruits As­traZeneca vet to steer Ku­ra's late-stage piv­ot

Sev­en months af­ter Ku­ra On­col­o­gy bid farewell with co-founder and chief med­ical of­fi­cer An­to­nio Gual­ber­to, the biotech has found his suc­ces­sor from the ranks of Big Phar­ma alum­ni.

With Phase II da­ta in hand for the lead drug, tip­i­farnib, and a sec­ond pro­gram al­most ready for the clin­ic, the biotech was look­ing for some­one well versed in tar­get­ed ther­a­py de­vel­op­ment and ex­pe­ri­enced with reg­u­la­tors, CEO Troy Wil­son told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER